Ultragenyx Pharma (RARE) Misses Q4 EPS by 2c

Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($2.16), $0.02 worse than the analyst estimate of ($2.14). Revenue for the quarter came in at $103.35 million versus the consensus estimate of $101.94 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Femasys Inc. (FEMY) Misses Q2 EPS by 20c
• UBS: 'We Believe Dollar Tree (DLTR) is Turning From a Transformation to a Growth Story'